Firing up the cold tumors by targeting Vps34

Bassam Janji*, Meriem Hasmim, Santiago Parpal, Guy Berchem, Muhammad Zaeem Noman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Citations (Scopus)


Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration. In our recent report published in Science Advances, we demonstrate that targeting the autophagy-related protein Vps34 switched cold immune desert tumors into hot inflamed immune-infiltrated tumors and enhanced the efficacy of anti-PD-1/PD-L1. Our study provides the preclinical rationale to set up combination immunotherapy clinical trials using selective Vps34 inhibitors and immune checkpoint blockers in melanoma and CRC.

Original languageEnglish
Article number1809936
Issue number1
Publication statusPublished - 1 Jan 2020


  • Autophagy
  • CCL5
  • CXCL10
  • NK cells
  • T CD8 lymphocytes
  • VPS34
  • anti-PD-1/PD-L1
  • cancer immunotherapy
  • cold/hot tumors
  • colon cancer
  • immune landscape
  • melanoma
  • proinflammatory cytokines


Dive into the research topics of 'Firing up the cold tumors by targeting Vps34'. Together they form a unique fingerprint.

Cite this